Mazdutide is another dual GLP-1 and glucagon receptor agonist, developed by Innovent Biologics under license from Eli Lilly. It works on the same two-pathway principle as survodutide.
What makes it worth knowing about is that it is already approved and on the market, just not in the West. China's regulator approved it for obesity in 2026, making it one of the first dual agonists approved anywhere in the world.
That is a notable shift. For most of the modern drug era, new medicines arrived in the United States and Europe first and reached other markets later. Mazdutide went the other way, and it is a reasonable signal of where obesity drug development is heading.
It has not been approved by the FDA or the European regulator, and it is not available by prescription in those markets.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
No reviews yet. Be the first.
AOD9604 is a fragment of human growth hormone — specifically the last 15 amino acids at one end of the molecul…
Cagrilintide is a long acting version of amylin, a hormone your pancreas releases alongside insulin whenever y…
CJC-1295 is a synthetic version of a hormone your body already produces called GHRH — growth hormone releasing…
The pivotal GLORY-1 trial enrolled 610 Chinese adults and reported roughly 13 percent placebo-adjusted weight reduction at the 6 mg dose by week 32. That result supported its approval in China.
Two things make the data worth reading carefully. The trial ran for 32 weeks, which is shorter than the 68 to 76 week trials behind most Western obesity drugs, and weight loss on these drugs usually continues past that point. So the number is not directly comparable to a 68 week result from a different trial.
The population also matters. Nearly all participants were Chinese adults. That is genuinely valuable, because obesity drug trials have historically been dominated by American and European participants, and there are real differences in how these drugs perform across populations. But it also means less is known about how it behaves elsewhere.
Mazdutide is a useful reminder that the obesity drug race is not only happening in the United States and Europe, and that approval in one country does not mean availability in another.